In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory clearance, secure new funding and contracts, enter strategic partnerships, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Presented new data showing that its HydroMID® midline catheter significantly reduced complications compared to a conventional CHG-coated catheter. The HydroMID catheter had a 95% therapy completion rate and a lower complication rate of 5%, outperforming the CHG catheter, despite longer dwell times.
Received a $7.45M sole-source, non-dilutive small business innovation research (SBIR) Phase III contract from the United States Air Force. Amsel developed SCureClamp™, a CE-marked, FDA-cleared mechanical surgical clamping technology delivered through a fine, minimally invasive 18 G needle.
Received FDA 510(k) clearance for its PlaqueIQ™ imaging analysis software to aid in the diagnosis of cardiovascular disease. PlaqueIQ™ is a non-invasive software capable of quantifying and classifying plaque morphology based on histology.
LSI Alumni Alpha Sophia and Greenlight Guru entered a strategic partnership. The partnership aims to accelerate market entry and reduce risks for medtech companies by combining Greenlight Guru’s cloud-based solutions for quality management and clinical data capture with Alpha Sophia’s advanced targeting platform.
Appointed Dr. Jessica DeLong, MD, FACS, as its Chief Medical Officer. The company is developing a precision neuromodulation micro-implant to treat pelvic health conditions, such as urinary incontinence, bowel incontinence, pelvic pain, sexual dysfunction, and pelvic floor disorders.
Secured FDA Class II clearance for its next-generation stethoscope, Keikku, and announced the upcoming U.S. launch of the device. Keikku turns each listening session into a data-rich moment, enabling AI-driven diagnostics across cardiac, respiratory, gastrointestinal, and obstetric care.
Received a Phase I SBIR contract from the NIH National Cancer Institute. The funds will support the development of a novel endoscopic imaging platform combining far-red fluorescence and reflected light imaging to detect esophageal cancer.
Added a fourth insight to the MIMOSA Pro for point-of-care wound assessments. In addition to tissue oximetry, temperature, and a digital image, the assessment will now include two-dimensional wound measurement.
Announced findings from a multicenter study on its EndoZip™ endoscopic suturing system for obesity treatment. The study demonstrated that the EndoZip™ system was associated with an average total body weight loss of 13.21% at 12 months.
Received a CE marking for its dedicated brain PET system, NeuroLFⓇ. The NeuroLFⓇ system is an imaging system with a small footprint that aids in diagnosing and monitoring brain-related conditions, such as Alzheimer’s disease, brain tumors, epilepsy, and Parkinson’s disease, among others.
Secured a $2M contract with the U.S. Department of Defense. The company is developing non-invasive brain scanners to enable faster detection and triage and continuous monitoring of brain injury.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
.png)
